CN101044142A - 嘌呤衍生物 - Google Patents
嘌呤衍生物 Download PDFInfo
- Publication number
- CN101044142A CN101044142A CNA2006800004415A CN200680000441A CN101044142A CN 101044142 A CN101044142 A CN 101044142A CN A2006800004415 A CNA2006800004415 A CN A2006800004415A CN 200680000441 A CN200680000441 A CN 200680000441A CN 101044142 A CN101044142 A CN 101044142A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- purine
- amino
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (10)
- 权 利 要 求1. 式 (Π )化合物, 其药物上可接受的溶剂化物或其水合 物,其中: M—表示药学上可接受的酸根阴离子,所述酸根阴离子 M—选自 pKa 小于 2.0 的无机酸或 pKa 小于 3.5的有机酸。
- 2. 权利要求 1 的化合物, 其中药物上可接受的无机酸选自 盐酸, 氢溴酸, 氢碘酸, 硫酸或硝酸。
- 3. 权利要求 1 的化合物, 其中药物上可接受的有机酸选自 甲磺酸, 马来酸, 酒石酸, 富马酸, 枸橼酸或草酸。
- 4. 权利要求 1-3 任一的化合物, 其为盐酸 [1S- ( 1 α, 3 , 4 β ) ]-2-氨基 -1, 9 -二氢 -9- [4-羟基 -3- (羟甲基) -2-亚 甲基环戊基] -6Η-嘌呤- 6-酮包括其药物上可接受的溶剂化物或其 水合物;甲磺酸 [lS- ( l a, 3α , 4 & ) ]-2-氨基-1, 9-二氢- 9- [4- 羟基- 3- (羟甲基) -2-亚甲基环戊基 ]-6H-嘌呤 -6-酮包括其药物 上可接受的溶剂化物或其水合物; 或马来酸 [IS- ( l a , 3α , 4 β ) ]- 2-氨基 -1, 9-二氢 -9- [4- 羟基 -3- (羟甲基) -2-亚甲基环戊基 ]-6H-嘌呤- 6-酮包括其药物 上可接受的溶剂化物或其水合物。
- 5. 权利要求 4 的化合物, 其中所述马来酸 [IS- ( 1α , 3 , 4 β ) ]- 2-氨基- 1, 9-二氢 -9- [4-羟基- 3- (羟甲基) -2 -亚 甲基环戊基] - 6Η-嘌呤 -6-酮水合物为马来酸 [IS- ( lo , 3α , 4 β ) ]-2-氨基 -1, 9-二氢- 9- [4-羟基 -3- (羟曱基) -2-亚曱基环 戊基] -6Η-嘌呤 -6-酮一水合物。
- 6. 含有权利要求 1-5 任一化合物, 其药物上可接受的溶剂 化物或其水合物及药用载体的药物组合物。
- 7. 一种制备权利要求 1-5 任一化合物的方法, 该方法包括 以甲醇或水为溶剂, 在室温下, 以等摩尔量或稍过量的适当的酸 为 Μ—阴离子源与 [IS- (1α, 3α, 4 ) ]-2-氨基-1, 9-二氢- 9- [4-羟基- 3- (羟甲基) -2-亚曱基环戊基 ]-6Η-嘌呤- 6-酮反应, 然后结晶出式 II化合物, 如果需要, 将所得式 II化合物转变为 其药用的溶剂化物或水合物。
- 8. 制备权利要求 1-5 任一化合物作为其活性成分的药物组 合物的方法, 该方法包括将有效量的活性成分与可在药物中应用 的载体相混合。
- 9. 权利要求 1-5 任一化合物在制备用于治疗人乙型肝炎病 毒感染和 /或并发感染药物中的用途。
- 10. 权利要求 9 的用途, 其中所述化合物为马来酸 [IS- (1 α, 3α, 4β ) ]-2-氨基 -1, 9-二氢 -9- [4-羟基- 3- (羟甲基) - 2 -亚曱基环戊基] -6Η-嘌呤 -6-酮一水合物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2005100748028A CN1699366A (zh) | 2005-06-03 | 2005-06-03 | 嘌呤衍生物 |
CN200510074802.8 | 2005-06-03 | ||
CN200510097848.1 | 2005-08-30 | ||
PCT/CN2006/001214 WO2006128389A1 (fr) | 2005-06-03 | 2006-06-05 | Derives de purine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101044142A true CN101044142A (zh) | 2007-09-26 |
CN100471857C CN100471857C (zh) | 2009-03-25 |
Family
ID=35475635
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005100748028A Pending CN1699366A (zh) | 2005-06-03 | 2005-06-03 | 嘌呤衍生物 |
CNA2005100978481A Pending CN1872853A (zh) | 2005-06-03 | 2005-08-30 | 嘌呤衍生物 |
CNB2006800004415A Active CN100471857C (zh) | 2005-06-03 | 2006-06-05 | 嘌呤衍生物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005100748028A Pending CN1699366A (zh) | 2005-06-03 | 2005-06-03 | 嘌呤衍生物 |
CNA2005100978481A Pending CN1872853A (zh) | 2005-06-03 | 2005-08-30 | 嘌呤衍生物 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR101319516B1 (zh) |
CN (3) | CN1699366A (zh) |
EA (1) | EA014043B1 (zh) |
WO (1) | WO2006128389A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1699366A (zh) * | 2005-06-03 | 2005-11-23 | 北京市典范科技有限责任公司 | 嘌呤衍生物 |
CN1907987B (zh) * | 2005-08-03 | 2010-05-05 | 江苏正大天晴药业股份有限公司 | 恩地卡韦酸加成盐及其制备方法和用途 |
CN101016299B (zh) * | 2006-02-09 | 2010-05-12 | 北京典范科技有限责任公司 | 制备嘌呤衍生物的新方法 |
AU2010307562B2 (en) * | 2009-10-12 | 2013-05-16 | Hanmi Science Co., Ltd. | Novel method for preparing entecavir and intermediate used therein |
CN112358481B (zh) | 2017-09-29 | 2022-02-22 | 广州市恒诺康医药科技有限公司 | 长效恩替卡韦前药及其制备方法和应用 |
CN109053734B (zh) * | 2018-08-24 | 2020-12-15 | 浙江爱诺生物药业股份有限公司 | 一种恩替卡韦粗品的纯化方法 |
KR102188965B1 (ko) | 2020-04-10 | 2020-12-09 | 강규영 | 폼방석 및 그 제조방법 |
CN114105987B (zh) * | 2020-08-26 | 2022-12-27 | 上海博志研新药物技术有限公司 | 恩替卡韦药用盐及其制备方法、药物组合物和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206244A (en) * | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
EP1644384B1 (en) * | 2002-12-11 | 2012-10-31 | Bristol-Myers Squibb Company | Process and intermediates for the synthesis of entecavir |
CN1699366A (zh) * | 2005-06-03 | 2005-11-23 | 北京市典范科技有限责任公司 | 嘌呤衍生物 |
-
2005
- 2005-06-03 CN CNA2005100748028A patent/CN1699366A/zh active Pending
- 2005-08-30 CN CNA2005100978481A patent/CN1872853A/zh active Pending
-
2006
- 2006-06-05 CN CNB2006800004415A patent/CN100471857C/zh active Active
- 2006-06-05 WO PCT/CN2006/001214 patent/WO2006128389A1/zh active Application Filing
- 2006-06-05 KR KR1020077030595A patent/KR101319516B1/ko not_active IP Right Cessation
- 2006-06-05 EA EA200702637A patent/EA014043B1/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20080033186A (ko) | 2008-04-16 |
CN100471857C (zh) | 2009-03-25 |
WO2006128389A1 (fr) | 2006-12-07 |
KR101319516B1 (ko) | 2013-10-21 |
CN1872853A (zh) | 2006-12-06 |
EA014043B1 (ru) | 2010-08-30 |
CN1699366A (zh) | 2005-11-23 |
EA200702637A1 (ru) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101044142A (zh) | 嘌呤衍生物 | |
KR100774271B1 (ko) | 발라사이클로비르 염산염의 결정질 형태 | |
CA2917183C (en) | Salts of dasatinib in crystalline form | |
EP3176173B1 (en) | Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof | |
CN111868057B (zh) | 一种二氢嘧啶类化合物的固体形式及其制备方法和用途 | |
RU2485121C1 (ru) | Новые кристаллические формы адефовира дипивоксила и способы его получения | |
CN111205290B (zh) | 一种jak激酶抑制剂的结晶形式及其制备方法 | |
RU2568638C1 (ru) | КРИСТАЛЛИЧЕСКАЯ β-МОДИФИКАЦИЯ 4-[4-({ [4-ХЛОРО-3-(ТРИФТОРОМЕТИЛ) ФЕНИЛ]КАРБАМОИЛ} АМИНО)ФЕНОКСИ]-N-МЕТИЛ-ПИРИДИН-2-КАРБОКСАМИДА п-ТОЛУОЛСУЛЬФОНАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ | |
HU229294B1 (en) | Crystal of pyrimidine nucleoside derivative | |
JPH10182639A (ja) | ドキサゾシン・メシレートの新規な形態i | |
CN111620879B (zh) | Pf-06651600马来酸盐,晶型及其制备方法 | |
CN111620880B (zh) | Pf-06651600 dl-酒石酸盐,晶型及其制备方法 | |
CN111732591B (zh) | Pf-06651600 l-酒石酸盐,晶型及其制备方法 | |
CN111670191B (zh) | 吡啶酮衍生物的晶型及制备方法和应用 | |
EP3004103A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5 d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
CN112125910A (zh) | 一种阿伐普替尼晶型及其制备方法 | |
RU2577518C2 (ru) | КРИСТАЛЛИЧЕСКАЯ БЕЗВОДНАЯ γ-МОДИФИКАЦИЯ 4-(3'-ХЛОР-4'-ФТОРАНИЛИНО)-7-МЕТОКСИ-6-(3-МОРФОЛИНОПРОПОКСИ)ХИНАЗОЛИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ | |
EP3004104A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
CN113398125B (zh) | 替唑尼特药物组合物及其医药用途 | |
RU2711106C2 (ru) | Кристаллическая μ-модификация 1-[(3R)-3-[4-амино-3-(4-фенокси-фенил)-1Н-пиразоло[3,4-d]пиримидин-1-ил]-1-пиперидил]-2-пропенил-1-она, способ её получения и фармацевтическая композиция на её основе | |
WO2017072543A1 (en) | Palbociclib salts | |
CN106831853B (zh) | 7-乙基-10-o-叔丁基二苯基硅基喜树碱-20-o-甘氨酸盐酸盐的制备工艺 | |
CN105315260A (zh) | 一种托布司他一水合物晶型及其制备方法 | |
CN116354967A (zh) | 一种核苷化合物的晶型及其制备方法和应用 | |
CN112142730A (zh) | 杂芳基并四氢吡啶类化合物的固体形式及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING EXAMPLE SCIENCE AND TECHNOLOGY CO., LTD. Owner name: JIANGSU CHIA-TAI TIANQING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING EXAMPLE SCIENCE AND TECHNOLOGY CO., LTD. Effective date: 20100429 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100055 NO.25, LIANHUA WEST ROAD, HAIDIAN, BEIJING CITY, CHINA TO: 222006 NO.8, JULONG NORTH ROAD, XINPU DISTRICT, LIANYUNGANG CITY |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100429 Address after: 222006 No. 8 Julong North Road, Sinpo District, Lianyungang Co-patentee after: Beijing Dianfan Science and Technology Co., Ltd. Patentee after: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Address before: 100055 No. 25 Lianhua West Road, Beijing, Haidian, China Patentee before: Beijing Dianfan Science and Technology Co., Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Yu Fei Document name: Notification of Passing Examination on Formalities |
|
C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Patentee after: Beijing Dianfan Science and Technology Co., Ltd. Address before: No. 8 Julong North Road, Sinpo District, Lianyungang Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Patentee before: Beijing Dianfan Science and Technology Co., Ltd. |